Vaccine and Infectious Disease Division

2010 VIDD Publications

1. Abu-Raddad LJ, Hilmi N, Mumtaz G, Benkirane M, Akala FA, Riedner G, et al. Epidemiology of HIV infection in the Middle East and North Africa. AIDS (London, England). 2010;24 Suppl 2:S5-23.

2. Alsallaq RA, Schiffer JT, Longini IM, Wald A, Corey L, Abu-Raddad LJ. Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2. Sexually transmitted diseases. 2010;37(5):290-7.

3. Asmuth DM, Brown EL, DiNubile MJ, Sun X, del Rio C, Harro C, et al. Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens. The Journal of infectious diseases. 2010;201(1):132-41.

4. Baeten JM, Donnell D, Kapiga SH, Ronald A, John-Stewart G, Inambao M, et al. Male circumcision and risk of male-to-female HIV-1 transmission: a multinational prospective study in African HIV-1-serodiscordant couples. AIDS (London, England). 2010;24(5):737-44.

5. Brown ER, Chen YQ. An Imputation Method for Interval Censored Time-to-Event with Auxiliary Information: Analysis of the Timing of Mother-to-Child Transmission of HIV. Statistical Communications in Infectious Diseases. 2010;2(1).

6. Burroughs LM, Torgerson TR, Storb R, Carpenter PA, Rawlings DJ, Sanders JE, et al. Stable hematopoietic cell engraftment after low-intensity nonmyeloablative conditioning in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. J Allergy Clin Immunol. 2010;126(5):1000-5.

7. Campbell AP, Chien JW, Kuypers J, Englund JA, Wald A, Guthrie KA, et al. Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT. The Journal of infectious diseases. 2010;201(9):1404-13.

8. Casper C, Englund J, Boeckh M. How I treat influenza in patients with hematologic malignancies. Blood. 2010;115(7):1331-42.

9. Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010;362(5):427-39.

10. Chao DL, Halloran ME, Longini IM. School opening dates predict pandemic influenza A(H1N1) outbreaks in the United States. The Journal of infectious diseases. 2010;202(6):877-80.

11. Chao DL, Halloran ME, Obenchain VJ, Longini IM. FluTE, a publicly available stochastic influenza epidemic simulation model. PLoS Comput Biol. 2010;6(1):e1000656.

12. Chen X, Kask AS, Crichton ML, McNeilly C, Yukiko S, Dong L, et al. Improved DNA vaccination by skin-targeted delivery using dry-coated densely-packed microprojection arrays. J Control Release. 2010;148(3):327-33.

13. Chen YQ. Semiparametric regression in size-biased sampling. Biometrics. 2010;66(1):149-58.

14. Chen YQ, Young A, Brown ER, Chasela CS, Fiscus SA, Hoffman IF, et al. Population attributable fractions for late postnatal mother-to-child transmission of HIV-1 in Sub-Saharan Africa. Journal of acquired immune deficiency syndromes (1999). 2010;54(3):311-6.

15. Cheng C, Gall JGD, Nason M, King CR, Koup RA, Roederer M, et al. Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. Journal of virology. 2010;84(1):630-8.

16. Church JD, Huang W, Mwatha A, Musoke P, Jackson JB, Bagenda D, et al. Analysis of HIV tropism in ugandan infants. Curr HIV Res. 2010;8(7):498-503.

17. Cook ED, Arnold KB, Hermos JA, McCaskill-Stevens W, Moody-Thomas S, Probstfield JL, et al. Impact of supplemental site grants to increase African American accrual for the Selenium and Vitamin E Cancer Prevention Trial. Clin Trials. 2010;7(1):90-9.

18. Cooper CJ, Metch B, Dragavon J, Coombs RW, Baden LR. Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients. JAMA. 2010;304(3):275-83.

19. Cooper TG, Noonan E, von Eckardstein S, Auger J, Baker HWG, Behre HM, et al. World Health Organization reference values for human semen characteristics. Hum Reprod Update. 2010;16(3):231-45.

20. Corbett NP, Blimkie D, Ho KC, Cai B, Sutherland DP, Kallos A, et al. Ontogeny of Toll-like receptor mediated cytokine responses of human blood mononuclear cells. PloS one. 2010;5(11):e15041.

21. Corey L, McElrath MJ. HIV vaccines: mosaic approach to virus diversity. Nat Med. 2010;16(3):268-70.

22. Curlin ME, Huang M-L, Lu X, Celum CL, Sanchez J, Selke S, et al. Frequent detection of human adenovirus from the lower gastrointestinal tract in men who have sex with men. PloS one. 2010;5(6):e11321.

23. Dhavala SS, Datta S, Mallick BK, Carroll RJ, Khare S, Lawhon SD, et al. Bayesian Modeling of MPSS Data: Gene Expression Analysis of Bovine Salmonella Infection. Journal of the American Statistical Association. 2010;105(491):956-67.

24. Dimitrov DT, Masse B, Boily M-C. Who Will Benefit from a Wide-Scale Introduction of Vaginal Microbicides in Developing Countries? Statistical Communications in Infectious Diseases. 2010;2(1).

25. Dinges WL, Richardt J, Friedrich D, Jalbert E, Liu Y, Stevens CE, et al. Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotype. Journal of virology. 2010;84(9):4461-8.

26. Dong L, Li P, Oenema T, McClurkan CL, Koelle DM. Public TCR use by herpes simplex virus-2-specific human CD8 CTLs. Journal of immunology (Baltimore, Md : 1950). 2010;184(6):3063-71.

27. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375(9731):2092-8.

28. Donnell D, Hughes JP, Fleming TR. Challenges in the design of HIV prevention trials in the United States. Journal of acquired immune deficiency syndromes (1999). 2010;55 Suppl 2:S136-40.

29. D'Souza MP, Frahm N. Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies. AIDS (London, England). 2010;24(6):803-9.

30. Duerr A. Update on mucosal HIV vaccine vectors. Current opinion in HIV and AIDS. 2010;5(5):397-403.

31. Dufresne A, Rainville P, Dodin S, Barré P, Masse B, Verreault R, et al. Hypnotizability and opinions about hypnosis in a clinical trial for the hypnotic control of pain and anxiety during pregnancy termination. Int J Clin Exp Hypn. 2010;58(1):82-101.

32. Finak G, Perez J-M, Weng A, Gottardo R. Optimizing transformations for automated, high throughput analysis of flow cytometry data. BMC Bioinformatics. 2010;11:546.

33. Fowler CC, Pao LI, Blattman JN, Greenberg PD. SHP-1 in T cells limits the production of CD8 effector cells without impacting the formation of long-lived central memory cells. Journal of immunology (Baltimore, Md : 1950). 2010;185(6):3256-67.

34. Fuchs J, Celum C, Wang J, Hughes JP, Sanchez J, Cowan F, et al. Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial. The Journal of infectious diseases. 2010;201(8):1164-8.

35. Gantt S, Kakuru A, Wald A, Walusansa V, Corey L, Casper C, et al. Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children. Pediatr Blood Cancer. 2010;54(5):670-4.

36. Gardella C, Huang M-L, Wald A, Magaret AS, Selke S, Morrow RA, et al. Rapid polymerase chain reaction assay to detect herpes simplex virus in the genital tract of women in labor. Obstet Gynecol. 2010;115(6):1209-16.

37. Gilbert PB. Some design issues in phase 2B vs phase 3 prevention trials for testing efficacy of products or concepts. Statistics in medicine. 2010;29(10):1061-71.

38. Gilbert PB, Jin Y. Semiparametric estimation of the average causal effect of treatment on an outcome measured after a postrandomization event, with missing outcome data. Biostatistics (Oxford, England). 2010;11(1):34-47.

39. Gilbert PB, Wang M, Wrin T, Petropoulos C, Gurwith M, Sinangil F, et al. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. The Journal of infectious diseases. 2010;202(4):595-605.

40. Gill DK, Huang Y, Levine GL, Sambor A, Carter DK, Sato A, et al. Equivalence of ELISpot assays demonstrated between major HIV network laboratories. PloS one. 2010;5(12):e14330.

41. Gollub EL, Morrow KM, Mayer KH, Koblin BA, Peterside PB, Husnik MJ, et al. Three city feasibility study of a body empowerment and HIV prevention intervention among women with drug use histories: Women FIT. J Womens Health (Larchmt). 2010;19(9):1705-13.

42. Gooley TA, Chien JW, Pergam SA, Hingorani SR, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091-101.

43. Graham BS, McElrath MJ, Keefer MC, Rybczyk K, Berger D, Weinhold KJ, et al. Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. PloS one. 2010;5(8):e11995.

44. Gratama JW, Boeckh M, Nakamura R, Cornelissen JJ, Brooimans RA, Zaia JA, et al. Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood. 2010;116(10):1655-62.

45. Gray G, Buchbinder S, Duerr A. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Current opinion in HIV and AIDS. 2010;5(5):357-61.

46. Guthrie KA, Yong M, Frieze D, Corey L, Fredricks DN. The impact of a change in antibacterial prophylaxis from ceftazidime to levofloxacin in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010;45(4):675-81.

47. Handel A, Longini IM, Antia R. Towards a quantitative understanding of the within-host dynamics of influenza A infections. Journal of the Royal Society, Interface / the Royal Society. 2010;7(42):35-47.

48. Holtzheimer PE, Veitengruber J, Wang CC, Krows M, Thiede H, Wald A, et al. Utility of the Beck Depression Inventory to screen for and track depression in injection drug users seeking hepatitis C treatment. Gen Hosp Psychiatry. 2010;32(4):426-32.

49. Huang Y. A Comparison of Testing Parameters and the Implementation of a Group Sequential Design for Equivalence Studies Using Paired-Sample Analysis. Statistics in Biopharmaceutical Research. 2010;2(3):336 - 47.

50. Janes H, Dominici F, Zeger S. On quantifying the magnitude of confounding. Biostatistics (Oxford, England). 2010;11(3):572-82.

51. Jaspan HB, Brothers AW, Campbell AJP, McGuire JK, Browd SR, Manley TJ, et al. Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline. The Pediatric infectious disease journal. 2010;29(4):379-81.

52. Kask AS, Chen X, Marshak JO, Dong L, Saracino M, Chen D, et al. DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge. Vaccine. 2010;28(47):7483-91.

53. Kim HN, Wang J, Hughes JP, Coombs R, Sanchez J, Reid S, et al. Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection. The Journal of infectious diseases. 2010;202(5):734-8.

54. Koelle DM, Magaret AS, Warren T, Schellenberg GD, Wald A. APOE genotype is associated with oral herpetic lesions but not genital or oral herpes simplex virus shedding. Sexually transmitted infections. 2010;86(3):202-6.

55. Kramer HB, Lavender KJ, Qin L, Stacey AR, Liu MKP, di Gleria K, et al. Elevation of intact and proteolytic fragments of acute phase proteins constitutes the earliest systemic antiviral response in HIV-1 infection. PLoS Pathog. 2010;6(5):e1000893.

56. Laing KJ, Magaret AS, Mueller DE, Zhao L, Johnston C, De Rosa SC, et al. Diversity in CD8(+) T cell function and epitope breadth among persons with genital herpes. J Clin Immunol. 2010;30(5):703-22.

57. Limaye AP, Boeckh M. CMV in critically ill patients: pathogen or bystander? Rev Med Virol. 2010;20(6):372-9.

58. Lindsay RWB, Darrah PA, Quinn KM, Wille-Reece U, Mattei LM, Iwasaki A, et al. CD8+ T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c+ dendritic cells but show redundancy in their requirement of TLR and nucleotide-binding oligomerization domain-like receptor signaling. Journal of immunology (Baltimore, Md : 1950). 2010;185(3):1513-21.

59. Lingappa J, Nakku-Joloba E, Magaret AS, Friedrich D, Dragavon J, Kambugu F, et al. Sensitivity and specificity of herpes simplex virus-2 serological assays among HIV-infected and uninfected urban Ugandans. Int J STD AIDS. 2010;21(9):611-6.

60. Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, Mujugira A, et al. Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet. 2010;375(9717):824-33.

61. Lingappa JR, Hughes JP, Wang RS, Baeten JM, Celum C, Gray GE, et al. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PloS one. 2010;5(9):e12598.

62. Mark KE, Wald A, Magaret AS, Selke S, Kuntz S, Huang M-L, et al. Rapidly cleared episodes of oral and anogenital herpes simplex virus shedding in HIV-infected adults. Journal of acquired immune deficiency syndromes (1999). 2010;54(5):482-8.

63. Marrazzo JM, Martin DH, Watts DH, Schulte J, Sobel JD, Hillier SL, et al. Bacterial vaginosis: identifying research gaps proceedings of a workshop sponsored by DHHS/NIH/NIAID. Sexually transmitted diseases. 2010;37(12):732-44.

64. Marrazzo JM, Thomas KK, Fiedler TL, Ringwood K, Fredricks DN. Risks for acquisition of bacterial vaginosis among women who report sex with women: a cohort study. PloS one. 2010;5(6):e11139.

65. Martin ET, Fairchok MP, Kuypers J, Magaret AS, Zerr DM, Wald A, et al. Frequent and prolonged shedding of bocavirus in young children attending daycare. The Journal of infectious diseases. 2010;201(11):1625-32.

66. Matrajt L, Longini IM. Optimizing vaccine allocation at different points in time during an epidemic. PloS one. 2010;5(11):e13767.

67. Mbopi-Keou F-X, Trottier S, Omar RF, Nkele NN, Fokoua S, Mbu ER, et al. A randomized, double-blind, placebo-controlled Phase II extended safety study of two Invisible Condom formulations in Cameroonian women. Contraception. 2010;81(1):79-85.

68. McElrath MJ. Immune responses to HIV vaccines and potential impact on control of acute HIV-1 infection. The Journal of infectious diseases. 2010;202 Suppl 2:S323-6.

69. McElrath MJ, Ballweber L, Terker A, Kreger A, Sakchalathorn P, Robinson B, et al. Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells. Antimicrobial agents and chemotherapy. 2010;54(2):763-72.

70. McElrath MJ, Haynes BF. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity. 2010;33(4):542-54.

71. Milano F, Campbell AP, Guthrie KA, Kuypers J, Englund JA, Corey L, et al. Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients. Blood. 2010;115(10):2088-94.

72. Miller FD, Abu-Raddad LJ. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc Natl Acad Sci USA. 2010;107(33):14757-62.

73. Moodie Z, Price L, Gouttefangeas C, Mander A, Janetzki S, Löwer M, et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother. 2010;59(10):1489-501.

74. Morishima C, Shuhart MC, Wang CC, Paschal DM, Apodaca MC, Liu Y, et al. Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology. 2010;138(2):671-81, 81.e1-2.

75. Morrison CS, Chen P-L, Kwok C, Richardson BA, Chipato T, Mugerwa R, et al. Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS (London, England). 2010;24(11):1778-81.

76. Novitsky V, Wang R, Bussmann H, Lockman S, Baum M, Shapiro R, et al. HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmission. PloS one. 2010;5(4):e10148.

77. Panackal AA, Li H, Kontoyiannis DP, Mori M, Perego CA, Boeckh M, et al. Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2010;50(12):1588-97.

78. Peiperl L, Morgan C, Moodie Z, Li H, Russell N, Graham BS, et al. Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054). PloS one. 2010;5(10):e13579.

79. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PIW, Walker BD, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010;330(6010):1551-7.

80. Phipps W, Ssewankambo F, Nguyen H, Saracino M, Wald A, Corey L, et al. Gender differences in clinical presentation and outcomes of epidemic Kaposi sarcoma in Uganda. PloS one. 2010;5(11):e13936.

81. Posavad CM, Remington M, Mueller DE, Zhao L, Magaret AS, Wald A, et al. Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons. Journal of immunology (Baltimore, Md : 1950). 2010;184(6):3250-9.

82. Reid SE, Dai JY, Wang J, Sichalwe BN, Akpomiemie G, Cowan FM, et al. Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women. Journal of acquired immune deficiency syndromes (1999). 2010;53(5):606-13.

83. Renaud C, Kuypers J, Corey L. Diagnostic accuracy of an allele-specific reverse transcriptase-PCR assay targeting the H275Y oseltamivir resistant mutation in 2009 pandemic influenza A/H1N1 virus. J Clin Virol. 2010;49(1):21-5.

84. Renaud C, Pergam SA, Polyak C, Jain R, Kuypers J, Englund JA, et al. Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir. Transpl Infect Dis. 2010;12(6):513-7.

85. Ribeiro RM, Qin L, Chavez LL, Li D, Self SG, Perelson AS. Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection. Journal of virology. 2010;84(12):6096-102.

86. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, Cost M, Huang Y, Gai F, et al. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PloS one. 2010;5(2):e9310.

87. Sabado RL, O'Brien M, Subedi A, Qin L, Hu N, Taylor E, et al. Evidence of dysregulation of dendritic cells in primary HIV infection. Blood. 2010;116(19):3839-52.

88. Sabatelli L. Effect of heterogeneous mixing and vaccination on the dynamics of anthelmintic resistance: a nested model. PloS one. 2010;5(5):e10686.

89. Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, Koelle DM, et al. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc Natl Acad Sci USA. 2010;107(44):18973-8.

90. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. Journal of virology. 2010;84(3):1439-52.

91. Siddique AK, Nair GB, Alam M, Sack DA, Huq A, Nizam A, et al. El Tor cholera with severe disease: a new threat to Asia and beyond. Epidemiol Infect. 2010;138(3):347-52.

92. Srinivasan S, Liu C, Mitchell CM, Fiedler TL, Thomas KK, Agnew KJ, et al. Temporal variability of human vaginal bacteria and relationship with bacterial vaginosis. PloS one. 2010;5(4):e10197.

93. Stoffer DS, Han S, Qin L, Guo W. Smoothing spline ANOPOW. Journal of Statistical Planning and Inference. 2010;140(12):3789 - 96.

94. Suthar MS, Ma DY, Thomas S, Lund JM, Zhang N, Daffis S, et al. IPS-1 is essential for the control of West Nile virus infection and immunity. PLoS Pathog. 2010;6(2):e1000757.

95. Tata S, Johnston C, Huang M-L, Selke S, Magaret AS, Corey L, et al. Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa. The Journal of infectious diseases. 2010;201(4):499-504.

96. Theiler RN, Farr SL, Karon JM, Paramsothy P, Viscidi R, Duerr A, et al. High-risk human papillomavirus reactivation in human immunodeficiency virus-infected women: risk factors for cervical viral shedding. Obstet Gynecol. 2010;115(6):1150-8.

97. Tjernlund A, Zhu J, Laing K, Diem K, McDonald D, Vazquez J, et al. In situ detection of Gag-specific CD8+ cells in the GI tract of SIV infected Rhesus macaques. Retrovirology. 2010;7:12.

98. Towler WI, James MM, Ray SC, Wang L, Donnell D, Mwatha A, et al. Analysis of HIV diversity using a high-resolution melting assay. AIDS research and human retroviruses. 2010;26(8):913-8.

99. Vaine M, Wang S, Liu Q, Arthos J, Montefiori D, Goepfert P, et al. Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies. PloS one. 2010;5(11):e13916.

100. Van Kerkhove MD, Asikainen T, Becker NG, Bjorge S, Desenclos J-C, dos Santos T, et al. Studies needed to address public health challenges of the 2009 H1N1 influenza pandemic: insights from modeling. PLoS Med. 2010;7(6):e1000275.

101. van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol. 2010;28(23):3701-8.

102. Watson-Jones D, Wald A, Celum C, Lingappa J, Weiss HA, Changalucha J, et al. Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials. J Clin Microbiol. 2010;48(10):3496-503.

103. Weinberg A, Song LY, Wilkening CL, Fenton T, Hural J, Louzao R, et al. Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assays. Journal of immunological methods. 2010;363(1):42-50.

104. Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116(24):5111-8.

105. Wolfson J, Gilbert PB. Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials. Biometrics. 2010;66(4):1153-61.

106. Yang Y, Halloran ME, Daniels MJ, Longini IM. Modeling Competing Infectious Pathogens from a Bayesian Perspective: Application to Influenza Studies with Incomplete Laboratory Results. Journal of the American Statistical Association. 2010;105(492):1310-22.

107. Zhang M, Gilbert PB. Increasing the Efficiency of Prevention Trials by Incorporating Baseline Covariates. Statistical communications in infectious diseases. 2010;2(1).